We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+17.65%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.6B
AUM Growth
+$135M
Cap. Flow
-$15.9M
Cap. Flow %
-0.99%
Top 10 Hldgs %
60.85%
Holding
38
New
3
Increased
13
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$46.5M
2
ALKS icon
Alkermes
ALKS
+$40.7M
3
NRIX icon
Nurix Therapeutics
NRIX
+$37.4M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$16.5M
5
MRUS
Merus
MRUS
+$7.83M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$45.4M
2
PCVX icon
Vaxcyte
PCVX
+$34.7M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$27.6M
4
COGT icon
Cogent Biosciences
COGT
+$21.4M
5
IMVT icon
Immunovant
IMVT
+$19.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Financials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THRD
26
DELISTED
Third Harmonic Bio
THRD
$18.4M 1.15%
1,360,569
-184,857
-12% -$2.29M
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.84B
$17M 1.06%
885,000
+60,000
+7% +$1.24M
APGE icon
28
Apogee Therapeutics
APGE
$10.2B
$17M 1.06%
290,000
– –
ABVX
29
Abivax
ABVX
$11B
$14.8M 0.92%
1,284,110
– –
TIL icon
30
Instil Bio
TIL
$48.4M
$10.2M 0.63%
+150,929
New +$3.55M
NGNE icon
31
Neurogene
NGNE
$696M
$8.39M 0.52%
200,000
– –
PCSC
32
DELISTED
Perceptive Capital Solutions
PCSC
$7.51M 0.47%
750,000
– –
BBOT
33
BridgeBio Oncology
BBOT
$707M
$5.22M 0.33%
500,000
– –
CABA icon
34
Cabaletta Bio
CABA
$439M
$5.19M 0.32%
1,100,000
– –
VTGN icon
35
VistaGen Therapeutics
VTGN
$9.29M
$4.74M 0.3%
1,575,000
– –
AVTX icon
36
Avalo Therapeutics
AVTX
$976M
$4.59M 0.29%
483,000
+443,000
+1,108% +$4.57M
AUTL
37
Autolus Therapeutics
AUTL
$386M
– –
-1,178,723
Closed -$4.1M
IMVT icon
38
Immunovant
IMVT
$8.09B
– –
-750,990
Closed -$19.8M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Commodore Capital held 38 positions worth $1.6B, up 9.2% from $1.47B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Commodore Capital's Q3 2024 filing shows 3 new, 13 increased, 9 reduced and 2 closed positions. Its largest new stake was Nurix Therapeutics: 1,650,000 shares worth $37.1M. The largest sale was Nuvalent, an estimated $45.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Commodore Capital's largest Q3 2024 buy was Nurix Therapeutics: 1,650,000 shares worth $37.1M.
  • Commodore Capital added most to Oruka Therapeutics in Q3 2024, an estimated $46.5M increase.
  • Commodore Capital's biggest Q3 2024 reduction was Nuvalent, cutting an estimated $45.4M.
  • Commodore Capital fully exited Immunovant in Q3 2024, selling an estimated $19.8M.
  • Commodore Capital's ten largest holdings make up 61% of its $1.6B portfolio in Q3 2024.
  • Commodore Capital opened 3 new positions and closed 2 in Q3 2024.
  • Commodore Capital's portfolio value rose 9.2% quarter-over-quarter to $1.6B.

Based on Commodore Capital's 13F filing for Q3 2024, filed 14 Nov 2024.